Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05292443
Other study ID # HisPower-Lib 002
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date December 20, 2021
Est. completion date March 17, 2023

Study information

Verified date February 2024
Source Geneplus-Beijing Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors


Description:

In the study, 300 advanced primery liver cancer patients who received immune checkpoint inhibitors at first-line setting (N=200) or second-line setting (N=100) will be recruited. By analyzing the ctDNA and peripheral blood mononuclear cell (PBMC) collected before and after the first cycle of ICI treatment, the dynamic changes of bTMB, ctDNA and the composition of immune cells will be detected. Combined with the tumor markers AFP, DCP and CA19-9, a noninvasive multiparameter model will be developed.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 17, 2023
Est. primary completion date March 17, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Primary liver cancer diagnosed according to the clinical diagnostic criteria, or histopathological or cytological examination; - 18-80 years old, no limit on gender; - ECOG performance status of 0-2, with expected survival time of more than 12 weeks; - According to RECIST V1.1, there must be at least one measurable lesion; - Patients who are suitable for ICIs treatment and willing to comply with required protocols and give permission to use the data for clinical research and products development; - Patients who join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up. Exclusion Criteria: - Patients with other primary cancers; - Patients with a severe parenchymal disease and unable to accept ICIs treatment; - Patients with a psychiatric disorder and unable to comply with this study; - Patients with symptomatic brain metastasis, anticipated complications or cognitive disorders that are associated with brain metastasis; - Adverse events related to prior anti-tumor treatment (except for hair loss of any grade) did not return to grade 1 or better; - History of cells or organ transplantation; - History of hypersensitivity to the drug administered in this study or contrast media for CT and MRI; - Patients who accepted hepatic local therapy (including ablation therapy, percutaneous injection of ethanol or acetic acid (PEI/PAI), high-intensity focused ultrasound (HIFU), transarterial chemoembolization (TACE)) within 14 days prior to initiation of the study; - Other reasons that the researchers think not suitable for ICIs treatment

Study Design


Intervention

Other:
Observation
observe the association of ctDNA with efficacy of treatment

Locations

Country Name City State
China Beijing hospital Beijing Beijing
China Xuanwu Hospital Capital Medical University Beijing Beijing
China Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, University of Chinese Academy of Sciences (UCAS) Chongqing Chongqing
China Eastern Hepatobiliary Surgery Hospital, Second Military Medical University Shanghai Shanghai
China Tongji Hospital affiliated to Tongji Medical College of Huazhong University Wuhan Hubei

Sponsors (2)

Lead Sponsor Collaborator
Geneplus-Beijing Co. Ltd. Eastern Hepatobiliary Surgery Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS: Progression-free survival The time length from the date of randomization to any of the following events: disease progression or death from any cause. 24 months
Secondary ORR: Objective Response Rate The proportion of patients with complete response or partial response. 24 months
Secondary OS: Overall Survival The time length from the date of randomization to the date of death. 24 months
Secondary TTD: Time to Treatment Discontinuation The time length from the date of randomization to the date of treatment discontinuation. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2